Tag Archives: BIO International Convention

Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors

BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions of therapeutic in-licensors and out-licensors were released today. The analysis looked at the meeting activity of 180 in-licensors attending the Chicago conference in terms of what therapeutic areas and stages of development were in highest demand. Of the 804 drug R&D companies, companies in Phase I/Rare Disease came out ahead as a group, with an average of >17 meetings/company. This was followed by Phase Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

AquAdvantage Salmon: A Regulatory Odyssey

AquAdvantage Salmon- A Regulatory Odyssey

At BIO 2012, an article was published on AquaBounty Technologies which told the tale of the Company’s New Animal Drug Application (NADA) for AquAdvantage Salmon.  At that time, the Company had completed all the required major elements for an FDA approval and FDA had held a thorough public airing before its Veterinary Medicine Advisory Committee (VMAC) of the results of the agency’s Center for Veterinary Medicine’s (CVM) review of AquaBounty’s application. Following the meeting of Read More >

Food And Agriculture  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Alzheimer’s Disease “Robs You of Everything”

Alzheimer’s Disease “Robs You of Everything”

George Hendrick and his wife, Mary Lee, experienced the typical highs and lows of parenthood as they raised nine children in New Lenox, a south suburb of Chicago. After the couple’s nest was nearly empty, in what was supposed to be their golden years, George was told he had memory and thinking problems, and later, Alzheimer’s disease. George’s long tenure as a Will County police officer was cut short. He could no longer carry a gun, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Venture Capital Trends

Venture Capital Trends

With industry data and numbers, results are always a mixed bag, says David Thomas, BIO’s Director of Industry Research & Analysis – and the latest on venture capital trends is no exception. In the U.S., biotech VC funding is flat, and start-up money is drying up. According to the National Venture Capital Association (NCVA), U.S. VC funding for biotech fell to $4.1 billion in 2012 (figure 1). This 17% drop was greater than the 10% Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Biomedical R&D in the 21st Century

Dale Edgar

Reflecting back upon my career,  I recognize the importance academic-industry research partnerships played in shaping my philosophy as a scientist and research leader.  Something deeply fulfilling happens when basic and applied scientists ally, and our individual passion to make a difference in the life of a patient merges into a community effort. We are moving ever closer to solving some of the toughest biomedical challenges of our time.  But this is also an era of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,